Atara Biotherapeutics (ATRA) versus BIONDVAX PHARMA/S (BVXV) Financial Survey

BIONDVAX PHARMA/S (NASDAQ:BVXV) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares BIONDVAX PHARMA/S and Atara Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BIONDVAX PHARMA/S N/A -773.59% -107.85%
Atara Biotherapeutics N/A -56.58% -51.33%

Analyst Ratings

This is a breakdown of current recommendations and price targets for BIONDVAX PHARMA/S and Atara Biotherapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BIONDVAX PHARMA/S 0 0 0 0 N/A
Atara Biotherapeutics 1 0 5 0 2.67

Atara Biotherapeutics has a consensus price target of $50.00, suggesting a potential upside of 48.41%. Given Atara Biotherapeutics’ higher possible upside, analysts plainly believe Atara Biotherapeutics is more favorable than BIONDVAX PHARMA/S.

Earnings and Valuation

This table compares BIONDVAX PHARMA/S and Atara Biotherapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BIONDVAX PHARMA/S N/A N/A -$23.41 million ($3.60) -1.83
Atara Biotherapeutics N/A N/A -$230.70 million ($5.27) -6.46

Atara Biotherapeutics is trading at a lower price-to-earnings ratio than BIONDVAX PHARMA/S, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

7.0% of BIONDVAX PHARMA/S shares are held by institutional investors. 6.0% of BIONDVAX PHARMA/S shares are held by insiders. Comparatively, 10.6% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

BIONDVAX PHARMA/S has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500.

Summary

Atara Biotherapeutics beats BIONDVAX PHARMA/S on 6 of the 10 factors compared between the two stocks.

About BIONDVAX PHARMA/S

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.